Alnylam Shares Rise 1.02 on 630M Volume as Gene Therapy Pipeline Drives Institutional Interest and 199th Market Activity Rank

On October 1, 2025, Alnylam Pharmaceuticals (ALNY) rose 1.02% with a trading volume of $630 million, ranking 199th in market activity. The biotech firm's shares saw renewed institutional interest following updates on its GSDI gene therapy pipeline, which showed encouraging Phase 2 trial data for rare disease indications. Analysts noted the stock's resilience amid sector-wide volatility, driven by positive momentum from its pipeline advancements and favorable regulatory risk profile.

Recent filings highlighted a strategic partnership with a European biotech entity to co-develop novel RNAi therapeutics targeting metabolic disorders. This collaboration, coupled with a revised 2026 R&D budget allocation, has bolstered investor confidence in the company's long-term capital efficiency. Institutional investors have been incrementally increasing exposure to the stock, with several large-cap funds adjusting their sector allocations to accommodate Alnylam's improved risk-reward dynamics.

Short-term technical indicators suggest continued consolidation above key support levels, with options activity showing increased call buying in the December 2025 cycle. The stock's performance appears decoupled from broader biotech index movements, reflecting its unique catalyst-driven valuation framework. However, near-term earnings revisions remain limited, with most analyst estimates unchanged since Q2 2025.

To run this back-test rigorously I need to pin down a few practical details that aren't fully specified yet: 1. Universe • Should we consider all U.S. common stocks (NYSE + NASDAQ + AMEX) or a narrower list such as the current S&P 500 constituents? • ADRs, ETFs and preferred shares are normally excluded – is that acceptable? 2. Ranking timestamp & trade execution • Typical workflow is: rank stocks by the ‟today” (T) dollar trading volume at the close, form the portfolio after the close, and enter positions at next-day (T+1) open, exiting at the same day’s close (one-day holding period). Is that the behaviour you want? 3. Weighting & rebalancing • Equal-weight across the 500 selected names each day, with full turnover every trading session (i.e., 100 % of the portfolio re-formed daily)? • Any transaction-cost assumption (e.g., 5 bps per side), or shall we ignore costs? If these defaults work for you I can proceed immediately; otherwise let me know your preferences so I can tailor the back-test accordingly.